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3rd-line therapy, analyzed from a third-party US payer perspective. Efficacy pa-
rameters included placebo-adjusted absolute weekly rates of remission and re-
sponse, taken from MDD treatment trials. Continuation, add-on, switch, and dis-
continuation rates, and inpatient and outpatient costs, were derived from the
PharMetrics database (Jan 2003–Mar 2008). Pharmacy costs were based on Whole-
sale Acquisition Costs. A budget impact model determined annual health care
costs of adding adjunct QTP XR to a formulary assuming a population of 185,000
patients,with 1.2%being treated forMDD.RESULTS:Adjunct QTPXR (300mg/d, but
not 150 mg/d) reduced total costs per remitting patient: $1998 versus adjunct ARP
when used in 2nd-line therapy ($17,168 vs $19,166) and $2608 in 3rd-line therapy
($22,051 vs $24,659). Themain drivers ofmodel outcomeswere pharmacy costs and
clinical efficacy. Probabilistic sensitivity analyses suggest model outcomes were
generally stable to varying assumptions. Increasing QTP XR use from 3.6% to 4.6%,
assuming a reduction in the use of other MDD treatments, increased overall health
care costs by 0.5% ($10,851,702–$10,909,591), with pharmacy costs rising by 2.3%
($3,006,169–$3,076,594). CONCLUSIONS: QTP XR (300 mg/d) as adjunct therapy, in
patients with MDD who previously have had an inadequate response to 1st- or
2nd-line therapy,was cost-effective in achieving remission comparedwith adjunct
ARP (15mg/d). Increasing QTP XR use as 2nd- or 3rd-line therapy had a limited and
well-defined budget impact. Supported by AstraZeneca Pharmaceuticals LP, Wil-
mington, Delaware.
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OBJECTIVES: In 2009, 8,211 hospitalizations for major depressive disorder (MDD)
occurred in Brazilian public hospitals, withmean duration of 20.5 days and average
cost of 770BRL. To inform decision-makers about more efficient therapeutic strat-
egies, this study aimed to compare costs of desvenlafaxine, escitalopram and du-
loxetine in the treatment of MDD inpatients from Brazilian public hospital
perspective.METHODS: A decision tree model was built to assess costs of desven-
lafaxine 50 mg/d, escitalopram 10 mg/d and duloxetine 60 mg/d to treat inpatients
admitted due to MDD. Four health states were considered: remission, dose escala-
tion due to lack of response, switching to another antidepressant after discontin-
uation caused by adverse event or failure, and treatment failure. This assessment
assumes similar efficacy among alternatives due to lack of head-to-head clinical
trials. Cost estimation assumed an 8-week time horizon. Relative risk of dropout
versus placebo was obtained through systematic review. Only direct medical costs
were considered and the cost components were drug acquisition costs and daily
room charges. One-way sensitivity analyses were performed using drug prices,
proportion of duloxetine patients requiring drug titration, and daily room charges
(20%) as key variables. RESULTS: Desvenlafaxine avoided 12% of estimated drop-
outs compared to competing alternatives. The estimated treatment costs were
1,955BRL, 2,213BRL and 2,476BRL per patient treated with desvenlafaxine, escita-
lopram and duloxetine, respectively. Therefore, desvenlafaxine exhibited savings
of257BRL and520BRL versus escitalopram and duloxetine, respectively.Within
sensitivity analyses, the lower saving was observed when duloxetine titration was
set as 0% (94BRL versus escitalopram) and the higher when a20% variation was
applied to daily room charges (-580BRL versus duloxetine). CONCLUSIONS: Des-
venlafaxine would be a cost-saving strategy compared to escitalopram and dulox-
etine in the treatment of patients admitted to the hospital due to MDD, given its
lower price and lower dropout rates as a consequence of side effects.
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OBJECTIVES: Depression symptoms in medically ill patients are known to ad-
versely impact treatment compliance, healthcare costs and outcomes. Thus, this
study aims to compare costs of desvenlafaxine, escitalopram and duloxetine in
medically ill inpatients with associated major depressive disorder (MDD) from the
Brazilian public general hospital perspective. METHODS: A decision-tree model
was built to assess costs of desvenlafaxine 50 mg/d, escitalopram 10 mg/d and
duloxetine 60 mg/d to treat patients with MDD in Brazilian public hospitals. Four
health states were considered: remission, dose escalation due to lack of response,
switching to another antidepressant after discontinuation caused by adverse
event, and treatment failure. Assessment assumed similar efficacy among alter-
natives due to lack of head-to-head clinical trials. Cost estimation assumed an
8-week time horizon. Relative risk of dropouts compared to placebo was obtained
through literature systematic review. Since the model assumed that hospitaliza-
tion are not due to MDD, only drug acquisition costs were considered in the base
case. Unit costs were: 3.09BRL, 4.04BRL and 6.91BRL for desvenlafaxine, escitalo-
pram and duloxetine, respectively. Official prices were obtained from 2010 CMED/
ANVISA list. One-way sensitivity analyses were performed using drug prices and
proportion of duloxetine patients requiring drug titration as key variables.
RESULTS: Desvenlafaxine avoided 12% of estimated dropouts compared to com-
peting alternatives. The estimated treatment costs were 144BRL, 250BRL and
364BRL per patient treated with desvenlafaxine, escitalopram and duloxetine, re-
spectively. Therefore, desvenlafaxine exhibited savings of 106BRL and 220BRL
versus escitalopram and duloxetine, respectively. Within the sensitivity analyses,
the lower and higher savings were observed when Brazilian public procurement
priceswere adopted (82BRL versus escitalopramand216BRL versus duloxetine).
CONCLUSIONS: Desvenlafaxine would be a cost-saving strategy compared to esci-
talopram and duloxetine in medically ill inpatients treated for MDD, due its lower
price and lower dropout rates as a consequence of side effects.
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OBJECTIVES: CYP450 enzyme activities have been associated with inter-individual
variability affecting efficacy and tolerability among non-psychotic major depres-
sive disorder (MDD) patients. Pre-prescription pharmacogenetic testing helps to
identify patients with increased risk for adverse reactions, lack of efficacy and
increased hospitalization costs. These test results could assist doctors to prescribe
alternative therapy or optimum doses. Present study is to estimate the cost effec-
tiveness of pre-prescription pharmacogenetic testing to assess the CYP450 enzyme
activity for the treatment of depression using selective serotonin reuptake inhibi-
tors (SSRIs).METHODS:Markov model was developed from societal perspective to
identify cost and quality adjusted lifemonths (QALM) gained for carrying out phar-
macogenetic testing compared to no test strategy. A systematic search of the liter-
ature was carried out to identify published evidence for associations between ad-
verse events, dropout rates and the three phenotypic groups: ultrafast
metabolizers, poor metabolizers and intermediate metabolizers. Potentially rele-
vant papers were used to derive the transitional probabilities, costs and sensitivity
as well as specificity of CYP450 enzyme testing technique. Multiple one-way sen-
sitivity analyses were performed to find the robustness of the model. RESULTS:
Projected outcomes associated with pre-prescription CYP450 testing strategy for a
patient with MDD was $4367/6.5 compared to $5634/6.4 QALM in no test strategy.
The testing strategywas found to be dominant between the above two options. The
model was found to be sensitive to utility values, cost of adverse events follow up,
percentage of ADRdropouts and remission rates.CONCLUSIONS:The study results
indicate that CYP450 genotype-guided SSRI treatment for depression is potentially
cost saving and leads to improved quality of life in patients. Yet the model is not
robust with respect to selected clinical and economic variables. Further studies
should be pursued to confirm the value of genotype-guided therapy before broadly
applying in the regular clinical practice
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OBJECTIVES: Human capital theory posits that education, experience and health
are the main contributors to the value of labor, measured as individual wage or
earnings. We quantified the effects of general physical and mental health on an-
nual wage and possible inefficiencies in reaching the wage frontier for a U.S. rep-
resentative population.METHODS:Weutilized theMedical Expenditure Panel Sur-
vey for 2000-2007 for individual economic and health measures and population
estimates. General health wasmeasured using validated instruments (SF-12 phys-
ical and mental scores). Annual wage was expressed in 2009 US dollars. Stochastic
frontier regression was used to estimate the impact of physical and mental health
on annual wage. The model estimated wage function and individual level ineffi-
ciency. Specifically, annual wage wasmodeled as a function of years of experience
and educational attainment, plus physical and mental health, controlling for gen-
der, race/ethnicity, and region. Sensitivity analyseswere conducted to examine the
impact of varying assumptions on the results. RESULTS: A one percent increase in
physical health status resulted in 0.32% (0.27% - 0.36%) increase of annualwage and
one percent increase in mental health status resulted in 0.13% (0.09% - 0.16%)
increase of annual wage. The summative elasticity of these two health factors is
greater than the elasticity of experience: 0.38% (0.36% - 0.39%). In addition better
physical and mental health are associated with higher productivity and smaller
variations of inefficacy and stochastic error variance. CONCLUSIONS: General
physical and mental health make significant contributions to human capital as
reflected in wages in the U.S., as well as in expected productivity gains. Deficits in
human health are estimated to leave potential productivity gains unrealized. The
relativemagnitude of the health effect compared to the experience effect supports
larger investments in access to health care.
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MEASURES OF MEDICATION ADHERENCE IN ORAL VERSUS LONG-ACTING
RISPERIDONE IN TEXAS MEDICAID PATIENTS WITH SCHIZOPHRENIA
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OBJECTIVES: Medication adherence has been shown to be an important factor in
preventing schizophrenia-related relapses, and long-acting injectable risperidone
has been shown to be effective in improving medication adherence. The objective
of this study was to determine the medication adherence rates of schizophrenic
patients treatedwith either oral risperidone only (oral cohort) or long-acting inject-
able risperidone/ oral risperidone (injectable cohort).METHODS: Texas Medic-
aid prescription claims data (January 2006 to December 2008) were analyzed for
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